Randomized Clinical Comparison of Everolimus-Eluting SYNERGY® and Biolimus-Eluting BioMatrix NeoFlex® Coronary Stents in Non-Selected Patients With Ischemic Heart Disease

Trial Profile

Randomized Clinical Comparison of Everolimus-Eluting SYNERGY® and Biolimus-Eluting BioMatrix NeoFlex® Coronary Stents in Non-Selected Patients With Ischemic Heart Disease

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms SORT-OUT VIII
  • Most Recent Events

    • 24 Apr 2017 Planned End Date changed from 31 Jul 2015 to 31 Dec 2020.
    • 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top